Request Demo
Last update 23 Mar 2025
ETH-155008
Last update 23 Mar 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms ETH 155008, ETH-155008 |
Target |
Action inhibitors |
Mechanism CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors), PIM3 inhibitors(Serine/threonine-protein kinase pim-3 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with ETH-155008NCT05758610
A Phase I Clinical Study of Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ETH-155008 Tablets in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Non-Hodgkin's Lymphoma
CTR20222130
ETH-155008 片在复发性或难治性急性髓系白血病和非霍奇金淋巴瘤患者中的安全性、耐受性 、药代动力学和初步疗效的 I 期临床研究
[Translation] Phase I clinical study of the safety, tolerability, pharmacokinetics and preliminary efficacy of ETH-155008 tablets in patients with relapsed or refractory acute myeloid leukemia and non-Hodgkin's lymphoma
NCT04840784
A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of ETH-155008 in Subjects With Relapsed or Refractory B-cell NHL, CLL/SLL and AML
100 Clinical Results associated with ETH-155008
Login to view more data
100 Translational Medicine associated with ETH-155008
Login to view more data
100 Patents (Medical) associated with ETH-155008
Login to view more data
100 Deals associated with ETH-155008
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Adult Acute Myeloblastic Leukemia | Phase 1 | China | 04 Nov 2022 | |
| Refractory acute myeloid leukemia | Phase 1 | China | 04 Nov 2022 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | China | 27 Oct 2022 | |
| Mantle-Cell Lymphoma | Phase 1 | China | 27 Oct 2022 | |
| Relapsing acute myeloid leukemia | Phase 1 | China | 27 Oct 2022 | |
| T-Cell Lymphoma | Phase 1 | China | 27 Oct 2022 | |
| Solid tumor | Phase 1 | China | 30 Jan 2022 | |
| Acute Myeloid Leukemia | Phase 1 | Australia | 29 Jun 2021 | |
| B-Cell Lymphoma | Phase 1 | Australia | 29 Jun 2021 | |
| Chronic Lymphocytic Leukemia | Phase 1 | Australia | 29 Jun 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free